Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Cady

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Headache|February 8, 2023
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experimentTodd J Schwedt, Ashley Martin, Steven Kymes, et al.
The Journal of Headache and Pain|February 8, 2022
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF studyPeter McAllister, Paul K Winner, Jessica Ailani, et al.
Headache|September 22, 2021
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headacheMichael J Marmura, Hans-Christoph Diener, Robert P Cowan, et al.
Headache|December 14, 2020
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2Hans-Christoph Diener, Michael J Marmura, Stewart J Tepper, et al.
The Journal of Headache and Pain|March 30, 2021
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trialsTimothy R Smith, Egilius L H Spierings, Roger Cady, et al.
The Journal of Headache and Pain|May 26, 2021
Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trialsTimothy R Smith, Egilius L H Spierings, Roger Cady, et al.
Headache|May 20, 2011
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response surveyRoger Cady, Jim Banks, Robert B Nett, et al.
Headache|April 25, 2022
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine preventionRichard B Lipton, Peter J Goadsby, David W Dodick, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Headache|February 8, 2023
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experimentTodd J Schwedt, Ashley Martin, Steven Kymes, et al.
The Journal of Headache and Pain|February 8, 2022
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF studyPeter McAllister, Paul K Winner, Jessica Ailani, et al.
Headache|September 22, 2021
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headacheMichael J Marmura, Hans-Christoph Diener, Robert P Cowan, et al.
Headache|December 14, 2020
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2Hans-Christoph Diener, Michael J Marmura, Stewart J Tepper, et al.
The Journal of Headache and Pain|March 30, 2021
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trialsTimothy R Smith, Egilius L H Spierings, Roger Cady, et al.
The Journal of Headache and Pain|May 26, 2021
Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trialsTimothy R Smith, Egilius L H Spierings, Roger Cady, et al.
Headache|May 20, 2011
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response surveyRoger Cady, Jim Banks, Robert B Nett, et al.
Headache|April 25, 2022
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine preventionRichard B Lipton, Peter J Goadsby, David W Dodick, et al.
Pageof 10